Prosecution Insights
Last updated: November 08, 2026
Application No. 19/420,126

MARKING ELEMENT FOR MARKING TISSUE

Non-Final OA §103§DP
Filed
Dec 15, 2025
Priority
Nov 29, 2019 — DE 102019132558.7 +2 more
Examiner
JOHNSON, GERALD
Art Unit
3797
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Somatex Medical Technologies GmbH
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
1y 9m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
535 granted / 680 resolved
+8.7% vs TC avg
Moderate +9% lift
Without
With
+9.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
13 currently pending
Career history
703
Total Applications
across all art units

Statute-Specific Performance

§101
4.6%
-35.4% vs TC avg
§103
55.6%
+15.6% vs TC avg
§102
27.1%
-12.9% vs TC avg
§112
4.8%
-35.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 680 resolved cases

Office Action

§103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on 04/08/2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 2, 3, 8, 17, and 18 are rejected under 35 U.S.C. 103 as being unpatentable over Dorn et al. (Pub. No.: US 2002/0183826) in view of Armstrong et al. (Pub. No.: US 2012/0303112). Consider claim 2, Dorn discloses a marker for marking body tissue (paragraph [0071], stent 52 has a proximal end 58 that abuts to the distal end surface of a platinum-iridium radiopaque marker band 60), the marker comprising: an elongated body extending along a longitudinal axis (paragraph [0064], Fig. 1f, stent 32 having an elongated body extending along a longitudinal axis), the elongated body being formed by a plurality of interconnected, elastic, webs, the plurality of webs forming a lattice structure with a plurality of crossing points (paragraph [0005], Fig. 1f, Stents are characterized by a lattice structure), wherein the marker is configured to transition between a radially compressed state and a radially expanded state (paragraph [0063], compressed self-expanding stent 32), wherein, when the marker is in the radially expanded state, the elongated body is constricted in a central longitudinal section to form two flared longitudinal sections, a first flared longitudinal section widening outwardly along the longitudinal axis from a first side of the central longitudinal section and a second flared longitudinal section widening outwardly along the longitudinal axis from a second side of the central longitudinal section (Figs. 1g and 1h, flaring of the longitudinal axis at either end of stent 32), wherein, when the marker is in the radially compressed state, the webs forming the elongated body extend along the longitudinal axis of the elongated body such that a length of the radially compressed marker, extending along the longitudinal axis, is greater than a length of the radially expanded marker, extending along the longitudinal axis (paragraph [0089], Figs. 5 and 6, self-expandable stents 228 length shrinks during expansion). Dorn does not specifically disclose wherein, at least a portion of the elongated body is formed from a hard plastic material containing embedded metal particles such that the elongated body is configured to provide an artifact under ultrasound imaging of the marker. Armstrong discloses wherein, at least a portion of the elongated body is formed from a hard plastic material containing embedded metal particles such that the elongated body is configured to provide an artifact under ultrasound imaging of the marker (paragraph [0089], Fig. 1, the stent 100 can be formed from a combination of metals and plastics to include polyester (such as polyethylene terephthalate or PET) as known in the art to be hard, see paragraph [0059], wherein the lattice can be imbibed with materials to aid the physician during ultrasound imaging (see paragraph [0114])). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to modify the marker as disclosed by Dorn with the marker as taught by Armstrong to aid the physician during ultrasound imaging (Armstrong, paragraph [0114]). Consider claim 3, the combination of Dorn and Armstrong discloses wherein each of the plurality of webs is formed from the hard plastic material containing embedded metal particles (Armstrong, paragraph [0089], Fig. 1, the stent 100 can be formed from a combination of metals and plastics to include polyester (such as polyethylene terephthalate or PET) as known in the art to be hard, see paragraph [0059]). Consider claim 8, the combination of Dorn and Armstrong discloses wherein the central longitudinal section comprises a sleeve configured to compress the central longitudinal section to a minimal diameter (paragraph [0040], a radially inward reaction force exerted by the sleeve and tip onto the stent keeps the proximal remainder of the stent length radially inwardly constrained). Consider claim 17, the combination of Dorn and Armstrong discloses wherein the hard plastic material containing embedded metal particles comprises one or more of a titanium alloy, nitinol, a wire mesh, and PEEK (paragraph [0069], nitinol). Consider claim 18, the combination of Dorn and Armstrong discloses wherein at least a portion of the elongated body is formed from a radiopaque material (paragraph [0071], stent 52 has a proximal end 58 that abuts to the distal end surface of a platinum-iridium radiopaque marker band 60). Claims 4 and 5 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Dorn and Armstrong in view of Niu (Pub. No.: US 2010/0173070). Consider claims 4, 5, the combination of Dorn and Armstrong does not specifically disclose wherein respective portions of each of the plurality of webs is affixed to each other at each of the crossing points of the lattice structure. Niu discloses wherein respective portions of each of the plurality of webs is affixed to each other at each of the crossing points of the lattice structure (paragraph [0145], implantable medical devices such as stents with nanofiber-enhanced surfaces are optionally fused or cross-linked at the points where the various fibers contact each other, see paragraph [0077]). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the webs as disclosed by the combination of Dorn and Armstrong with the webs as taught by Niu to create a more stable, robust and potentially rigid fibrous membrane (Niu, paragraph [0077]). Claims 6 and 7 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Dorn, Armstrong, and Niu in view of Hyodoh et al. (Pub. No.: 2003/0040772, Applicant’s IDS filed 04/08/2026). Consider claim 6, the combination of Dorn, Armstrong, and Niu does not specifically disclose wherein the respective portions of each of the plurality of webs are twisted together at each of the crossing points. Hyodoh discloses wherein the respective portions of each of the plurality of webs are twisted together at each of the crossing points (paragraph [0149], Fig. 50C, segments 812 and 814 are twisted together). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the webs as disclosed by the combination of Dorn, Armstrong, and Niu with the webs as taught by Hyodoh to suit a particular application (Hyodoh, paragraph [0149]). Consider claim 7, the combination of Dorn, Armstrong, Niu, and Hyodoh discloses wherein the plurality of webs is pairwise interconnected at respective longitudinal ends of the plurality of webs (Hyodoh, paragraph [0149], Fig. 50C, segments 812 and 814 are twisted together at respective longitudinal ends). Claims 9-11 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Dorn and Armstrong in view of Horrigan (Pub. No.: US 2006/0041269). Consider claim 9, the combination of Dorn and Armstrong discloses does not specifically disclose wherein each of the first and second flared longitudinal sections widens outwardly at a constant angle relative to the longitudinal axis from the central longitudinal section to each longitudinal end of the marker. Horrigan discloses wherein each of the first and second flared longitudinal sections widens outwardly at a constant angle relative to the longitudinal axis from the central longitudinal section to each longitudinal end of the marker (paragraphs [0032] thru [0034], Fig. 2, similar to proximal portion 108, distal portion 110 may extend distally at a constant outer diameter to the proximal end of distal tapered surface 115). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the marker as disclosed by Dorn with the marker as taught by Horrigan to assure that the isolated treatment space 201 is sufficient for a particular procedure while still allowing blood to flow through the device (Horrigan, paragraph [0033]). Consider claim 10, the combination of Dorn, Armstrong, and Horrigan discloses wherein a maximum external diameter of each of the first and second flared longitudinal sections is about two times to twenty times larger than an external diameter of the central longitudinal section (Horrigan, Fig. 2, outer diameter of each of the extending proximal portion 108 and extending distal portion 110 is at least two times larger than an external diameter of the neck portion 112. Consider claim 11, the combination of Dorn, Armstrong, and Horrigan discloses wherein the elongated body is rotationally symmetric in relation to the longitudinal axis (Horrigan, Fig. 2, the elongated body is rotationally symmetric in relation to the guidewire 126). Claims 12 and 13 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Dorn and Armstrong in view of Hornscheidt et al. (WO 2017207777, Applicant’s IDS filed 04/08/2026). Consider claim 12, the combination of Dorn and Armstrong discloses an implantation system (paragraph [0001], delivery device for an implant such as a stent) comprising: the marker of claim 2 (paragraph [0071], stent 52 has a proximal end 58 that abuts to the distal end surface of a platinum-iridium radiopaque marker band 60); and an implantation apparatus comprising a catheter (paragraph [0058], Fig. 1a, The catheter is a stent delivery device), the marker being situated within the catheter (paragraph [0071], band 60 is fixed at a step 62 in the radial wall thickness of the inner shaft 56 of catheter 50) and being configured to be deployed from the catheter via actuation of the implantation apparatus (paragraph [0064], deployment of the stent from the catheter 16). The combination of Dorn and Armstrong does not specifically disclose the use of a cannula. Hornscheidt discloses the use of a cannula (page 5, lines 4-13, a marking device which can be placed and implanted in tissue via a cannula). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the catheter as disclosed by the combination of Dorn and Armstrong with the cannula as taught by Hornscheidt to provide an alignment-independent visibility in imaging methods, especially in the case of ultrasound-based methods (page 5, lines 4-13). Consider claim 13, the combination of Dorn and Armstrong does not specifically disclose wherein the implantation system is configured for application within a vacuum biopsy unit and wherein the cannula comprises a lateral opening for deploying the marker. Hornscheidt discloses wherein the implantation system is configured for application within a vacuum biopsy unit (page 3, lines 6-11, a vacuum biopsy), and wherein the cannula comprises a lateral opening for deploying the marker (page 3, lines 12-20, and claim 16, a cannula (242) having a lateral opening for deploying a marking device (100)). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the implantation system as disclosed by the combination of Dorn and Armstrong with the implantation system as taught by Hornscheidt to prevent the marking device from falling back into the biopsy cannula (Hornscheidt, page 3, lines 6-11). Claims 14, 15, and 16 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Dorn and Armstrong in view of Cerchiari et al. (Pub. No.: US 2017/0340434). Consider claim 14, the combination of Dorn and Armstrong does not specifically disclose wherein, when the marker is in the radially expanded state, the artifact includes a cross shape when the marker is viewed from a side of the marker. Cerchiari discloses wherein, when the marker is in the radially expanded state, the artifact includes a cross shape when the marker is viewed from a side of the marker (paragraphs [0066], [0085], Fig. 7, markers 194 (or Figs. 13, 14, markers 602, 604) may be positioned at the ends of the intermediate region and/or at the proximal end and/or distal end of the graft material, wherein in the expanded state one can envisage a cross shape (dog-bone shape, see paragraph [0016]) when visualized with a medical imaging system, such as ultrasound). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace marker as disclosed by the combination of Dorn and Armstrong with the marker as taught by Cerchiari to indicate the proximal and/or distal boundaries of the intermediate region when visualized with a medical imaging system, such as ultrasound (Cerchiari, paragraph [0085]). Consider claims 15, 16, the combination of Dorn and Armstrong does not specifically disclose wherein the portions of the elongated body formed from the hard plastic material containing embedded metal particles are selected to provide a symmetrically shaped artifact under ultrasound imaging of the marker. Cerchiari discloses wherein the portions of the elongated body formed from the hard plastic material containing embedded metal particles are selected to provide a symmetrically shaped artifact under ultrasound imaging of the marker (Cerchiari, paragraphs [0066], [0085], Fig. 7, markers 194 (or Figs. 13, 14, markers 602, 604) may be positioned at the ends of the intermediate region and/or at the proximal end and/or distal end of the graft material, wherein in the expanded state one can envisage an X-shaped structure (dog-bone shape, see paragraph [0016]) when visualized with a medical imaging system, such as ultrasound). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace marker as disclosed by the combination of Dorn and Armstrong with the marker as taught by Cerchiari to indicate the proximal and/or distal boundaries of the intermediate region when visualized with a medical imaging system, such as ultrasound (Cerchiari, paragraph [0085]). Claim 19 is rejected under 35 U.S.C. 103 as being unpatentable over the combination of Dorn and Armstrong in view of Drasler et al. (Pub. No.: US 2015/0306359). Consider claim 19, the combination of Dorn and Armstrong does not specifically disclose wherein each of the first and second flared longitudinal sections is formed from the hard plastic material containing embedded metal particles to generate a high acoustic impedance contrast with the body tissue. Drasler discloses wherein each of the first and second flared longitudinal sections is formed from the hard plastic material containing embedded metal particles to generate a high acoustic impedance contrast with the body tissue (paragraph [0063], Echogenic marker bands can be formed from a composite of materials having a large difference in acoustic impedance from the surrounding tissues and applied to RO marker materials such as radiopaque (RO) marker bands 113 and echogenic marker bands 112, see paragraph [0059], Fig. 6A). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to modify the first and second flared longitudinal sections as disclosed by the combination of Dorn and Armstrong with the RO marker materials as taught by Drasler to allow the ultrasound to visualize the tissue of the body (Drasler, paragraph [0063]). Claims 20, 23, and 24 are rejected under 35 U.S.C. 103 as being unpatentable over Dorn in view of Horrigan and further in view of Drasler. Consider claim 20, Dorn discloses a marker for marking body tissue (paragraph [0071], stent 52 has a proximal end 58 that abuts to the distal end surface of a platinum-iridium radiopaque marker band 60), the marker comprising: an elongated body extending along a longitudinal axis (paragraph [0064], Fig. 1f, stent 32 having an elongated body extending along a longitudinal axis), the elongated body being formed by a plurality of interconnected, elastic, webs, the plurality of webs forming a lattice structure (paragraph [0005], Fig. 1f, Stents are characterized by a lattice structure), wherein the marker is configured to transition between a radially compressed state and a radially expanded state (paragraph [0063], compressed self-expanding stent 32), wherein, when the marker is in the radially expanded state, the elongated body is constricted in a central longitudinal section to form two flared longitudinal sections, a first flared longitudinal section widening outwardly along the longitudinal axis from a first side of the central longitudinal section and a second flared longitudinal section widening outwardly along the longitudinal axis from a second side of the central longitudinal section (Figs. 1g and 1h, flaring of the longitudinal axis at either end of stent 32). Dorn does not specifically disclose each of the first and second flared longitudinal sections widening outwardly at a constant angle relative to the longitudinal axis from the central longitudinal section to each longitudinal end of the marker. Horrigan discloses each of the first and second flared longitudinal sections widening outwardly at a constant angle relative to the longitudinal axis from the central longitudinal section to each longitudinal end of the marker (paragraphs [0032] thru [0034], Fig. 2, similar to proximal portion 108, distal portion 110 may extend distally at a constant outer diameter to the proximal end of distal tapered surface 115). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the marker as disclosed by Dorn with the marker as taught by Horrigan to assure that the isolated treatment space 201 is sufficient for a particular procedure while still allowing blood to flow through the device (Horrigan, paragraph [0033]). The combination of Dorn and Horrigan does not specifically disclose wherein, the elongated body is configured to be detectable under B-mode ultrasound imaging of the marker in a frequency range from 1 MHz to 40 MHz. Drasler discloses wherein, the elongated body is configured to be detectable under B-mode ultrasound imaging of the marker in a frequency range from 1 MHz to 40 MHz (paragraph [0027], ultrasound imaging of an echogenic marker in a frequency range of 3-15 MHz). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the marker as disclosed by the combination of Dorn and Horrigan with the marker as taught by Drasler to absorb energy of the echo and be easily seen by echo (Drasler, paragraph [0027]). Consider claims 23, 24, the combination of Dorn and Horrigan does not specifically disclose wherein the elongated body is configured to achieve a predetermined ultrasound reflection level and a predetermined proportion of transmitted ultrasound energy under B-mode ultrasound imaging. Drasler discloses wherein the elongated body is configured to achieve a predetermined ultrasound reflection level and a predetermined proportion of transmitted ultrasound energy under B-mode ultrasound imaging (paragraphs [0027], [0063], echogenic marker bands can be formed from echogenic material such as reflective materials having a large difference in acoustic impedance from the surrounding tissues, wherein the frequency of the sound wave is approximately 10 MHz). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the marker as disclosed by the combination of Dorn and Horrigan with the marker as taught by Drasler to absorb energy of the echo and be easily seen by echo (Drasler, paragraph [0027]). Claims 21 and 22 are rejected under 35 U.S.C. 103 as being unpatentable over Dorn, Horrigan, and Drasler in view of Cerchiari et al. (Pub. No.: US 2017/0340434). Consider claim 21, the combination of Dorn, Horrigan, and Drasler does not specifically disclose wherein, when the marker is in the radially expanded state, the first and second flared longitudinal sections are configured to produce a characteristic imaging artifact under B-mode ultrasound imaging of the marker, the characteristic imaging artifact taking a form of a symmetrical shape that is distinguishable from the body tissue. Cerchiari discloses wherein, when the marker is in the radially expanded state, the first and second flared longitudinal sections are configured to produce a characteristic imaging artifact under B-mode ultrasound imaging of the marker, the characteristic imaging artifact taking a form of a symmetrical shape that is distinguishable from the body tissue (paragraphs [0066], [0085], Fig. 7, markers 194 (or Figs. 13, 14, markers 602, 604) may be positioned at the ends of the intermediate region and/or at the proximal end and/or distal end of the graft material, wherein in the expanded state one can envisage a cross shape (dog-bone shape, see paragraph [0016]) when visualized with a medical imaging system, such as ultrasound). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace marker as disclosed by the combination of Dorn, Horrigan, and Drasler with the marker as taught by Cerchiari to indicate the proximal and/or distal boundaries of the intermediate region when visualized with a medical imaging system, such as ultrasound (Cerchiari, paragraph [0085]). Consider claim 22, the combination of Dorn, Horrigan, Drasler, and Cerchiari discloses wherein the characteristic imaging artifact takes the form of a substantially circular or X-shaped structure (Cerchiari, paragraphs [0066], [0085], Fig. 7, markers 194 (or Figs. 13, 14, markers 602, 604) may be positioned at the ends of the intermediate region and/or at the proximal end and/or distal end of the graft material, wherein in the expanded state one can envisage an X-shaped structure (dog-bone shape, see paragraph [0016]) when visualized with a medical imaging system, such as ultrasound). Claims 25 and 26 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Dorn, Horrigan, and Drasler in view of Hornscheidt et al. (WO 2017207777, Applicant’s IDS filed 04/08/2026). Consider claim 25, the combination of Dorn, Horrigan, and Drasler discloses an implantation system (paragraph [0001], delivery device for an implant such as a stent) comprising: the marker of claim 2 (paragraph [0071], stent 52 has a proximal end 58 that abuts to the distal end surface of a platinum-iridium radiopaque marker band 60); and an implantation apparatus comprising a catheter (paragraph [0058], Fig. 1a, The catheter is a stent delivery device), the marker being situated within the catheter (paragraph [0071], band 60 is fixed at a step 62 in the radial wall thickness of the inner shaft 56 of catheter 50) and being configured to be deployed from the catheter via actuation of the implantation apparatus (paragraph [0064], deployment of the stent from the catheter 16). The combination of Dorn, Horrigan, and Drasler does not specifically disclose the use of a cannula. Hornscheidt discloses the use of a cannula (page 5, lines 4-13, a marking device which can be placed and implanted in tissue via a cannula). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the catheter as disclosed by the combination of Dorn, Horrigan, and Drasler with the cannula as taught by Hornscheidt to provide an alignment-independent visibility in imaging methods, especially in the case of ultrasound-based methods (page 5, lines 4-13). Consider claim 26, the combination of Dorn, Horrigan, and Drasler does not specifically disclose wherein the implantation system is configured for application within a vacuum biopsy unit and wherein the cannula comprises a lateral opening for deploying the marker. Hornscheidt discloses wherein the implantation system is configured for application within a vacuum biopsy unit (page 3, lines 6-11, a vacuum biopsy), and wherein the cannula comprises a lateral opening for deploying the marker (page 3, lines 12-20, and claim 16, a cannula (242) having a lateral opening for deploying a marking device (100)). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the implantation system as disclosed by the combination of Dorn, Horrigan, and Drasler with the implantation system as taught by Hornscheidt to prevent the marking device from falling back into the biopsy cannula (Hornscheidt, page 3, lines 6-11). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 2 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,521,202 in view of Armstrong et al. (Pub. No.: US 2012/0303112). Examined Application U.S. Patent No. 12,521,202 2. (New) A marker for marking body tissue, the marker comprising: an elongated body extending along a longitudinal axis, the elongated body being formed by a plurality of interconnected, elastic, webs, the plurality of webs forming a lattice structure with a plurality of crossing points, wherein the marker is configured to transition between a radially compressed state and a radially expanded state, wherein, when the marker is in the radially expanded state, the elongated body is constricted in a central longitudinal section to form two flared longitudinal sections, a first flared longitudinal section widening outwardly along the longitudinal axis from a first side of the central longitudinal section and a second flared longitudinal section widening outwardly along the longitudinal axis from a second side of the central longitudinal section, wherein, when the marker is in the radially compressed state, the webs forming the elongated body extend along the longitudinal axis of the elongated body such that a length of the radially compressed marker, extending along the longitudinal axis, is greater than a length of the radially expanded marker, extending along the longitudinal axis, and wherein, at least a portion of the elongated body is formed from a hard plastic material containing embedded metal particles such that the elongated body is configured to provide an artifact under ultrasound imaging of the marker. 1. A marking body for marking body tissue, the marking body having a longitudinal axis and being rotationally symmetric in relation to the longitudinal axis, wherein the marking body is formed by interconnected, elastic, preformed metal webs, the metal webs forming a lattice structure with a plurality of crossing points, respective portions of each of the metal webs being affixed to each other at each of the crossing points of the lattice structure, wherein the marking body is configured to transition between a radially compressed state and a radially expanded state, wherein, when the marking body is in the radially expanded state, the marking body is constricted in a central longitudinal section to form two flared longitudinal sections, a first flared longitudinal section widening outwardly along the longitudinal axis from a first side of the central longitudinal section and a second flared longitudinal section widening outwardly along the longitudinal axis from a second side of the central longitudinal section, each of the first and second flared longitudinal sections widening outwardly at a constant angle relative to the longitudinal axis from the central longitudinal section to each longitudinal end of the marking body such that a maximum external diameter of each of the first and second flared longitudinal sections is about two times to twenty times larger than an external diameter of the central longitudinal section, and at least the first and second flared longitudinal sections are formed by 5 to 96 webs in a circumferential direction of the marking body, and wherein, when the marking body is in the radially compressed state the metal webs forming the marking body extend along the longitudinal axis of the marking body and are interconnected in a force fit, interlocking, and/or cohesive fashion, such that a compressed length of the marking body, extending along the longitudinal axis, is greater than an expanded length of the marking body. The patent fails to teach wherein, at least a portion of the elongated body is formed from a hard plastic material containing embedded metal particles such that the elongated body is configured to provide an artifact under ultrasound imaging of the marker. Armstrong discloses wherein, at least a portion of the elongated body is formed from a hard plastic material containing embedded metal particles such that the elongated body is configured to provide an artifact under ultrasound imaging of the marker (paragraph [0089], Fig. 1, the stent 100 can be formed from a combination of metals and plastics to include polyester (such as polyethylene terephthalate or PET) as known in the art to be hard, see paragraph [0059], wherein the lattice can be imbibed with materials to aid the physician during ultrasound imaging (see paragraph [0114])). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to modify the marker as disclosed by the patent with the marker as taught by Armstrong to aid the physician during ultrasound imaging (Armstrong, paragraph [0114]). Claim 20 is rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 12,521,202 in view of Drasler et al. (Pub. No.: US 2015/0306359). Examined Application U.S. Patent No. 12,521,202 20. (New) A marker for marking body tissue, the marker comprising: an elongated body extending along a longitudinal axis, the elongated body being formed by a plurality of interconnected, elastic, webs, the plurality of webs forming a lattice structure, wherein the marker is configured to transition between a radially compressed state and a radially expanded state, wherein, when the marker is in the radially expanded state, the elongated body is constricted in a central longitudinal section to form two flared longitudinal sections, a first flared longitudinal section widening outwardly along the longitudinal axis from a first side of the central longitudinal section and a second flared longitudinal section widening outwardly along the longitudinal axis from a second side of the central longitudinal section, each of the first and second flared longitudinal sections widening outwardly at a constant angle relative to the longitudinal axis from the central longitudinal section to each longitudinal end of the marker, and wherein, the elongated body is configured to be detectable under B-mode ultrasound imaging of the marker in a frequency range from 1 MHz to 40 MHz. 1. A marking body for marking body tissue, the marking body having a longitudinal axis and being rotationally symmetric in relation to the longitudinal axis, wherein the marking body is formed by interconnected, elastic, preformed metal webs, the metal webs forming a lattice structure with a plurality of crossing points, respective portions of each of the metal webs being affixed to each other at each of the crossing points of the lattice structure, wherein the marking body is configured to transition between a radially compressed state and a radially expanded state, wherein, when the marking body is in the radially expanded state, the marking body is constricted in a central longitudinal section to form two flared longitudinal sections, a first flared longitudinal section widening outwardly along the longitudinal axis from a first side of the central longitudinal section and a second flared longitudinal section widening outwardly along the longitudinal axis from a second side of the central longitudinal section, each of the first and second flared longitudinal sections widening outwardly at a constant angle relative to the longitudinal axis from the central longitudinal section to each longitudinal end of the marking body such that a maximum external diameter of each of the first and second flared longitudinal sections is about two times to twenty times larger than an external diameter of the central longitudinal section, and at least the first and second flared longitudinal sections are formed by 5 to 96 webs in a circumferential direction of the marking body, and wherein, when the marking body is in the radially compressed state the metal webs forming the marking body extend along the longitudinal axis of the marking body and are interconnected in a force fit, interlocking, and/or cohesive fashion, such that a compressed length of the marking body, extending along the longitudinal axis, is greater than an expanded length of the marking body. The patent fails to teach wherein, the elongated body is configured to be detectable under B-mode ultrasound imaging of the marker in a frequency range from 1 MHz to 40 MHz. Drasler discloses wherein, the elongated body is configured to be detectable under B-mode ultrasound imaging of the marker in a frequency range from 1 MHz to 40 MHz (paragraph [0027], ultrasound imaging of an echogenic marker in a frequency range of 3-15 MHz). Therefore, it would have been obvious to one having ordinary skill in the art before the effectively filing date of the claimed invention to replace the marker as disclosed by the patent with the marker as taught by Drasler to absorb energy of the echo and be easily seen by echo (Drasler, paragraph [0027]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to GERALD JOHNSON whose telephone number is (571)270-7685. The examiner can normally be reached Monday-Friday 8am-5pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Carey Michael can be reached at (571)270-7235. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Gerald Johnson/ Primary Examiner, Art Unit 3797
Read full office action

Prosecution Timeline

Dec 15, 2025
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778549
INTRALUMINAL ULTRASOUND ASSEMBLY HAVING A MULTIPLE MATERIAL SUPPORT MEMBER, AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS
1y 10m to grant Granted Nov 03, 2026
Patent 12778503
METHOD AND SYSTEM FOR ESTIMATION OF ABDOMINAL FAT
1y 8m to grant Granted Nov 03, 2026
Patent 12773574
METHOD AND APPARATUS FOR STEREOTACTIC BODY RADIATION TREATMENT PLANNING AND ADMINISTRATION
4y 4m to grant Granted Oct 27, 2026
Patent 12758099
OPTICAL BIOMEDICAL MEASUREMENT DEVICE
2y 4m to grant Granted Oct 13, 2026
Patent 12752022
SINGLE-POLYMER PARTICLES, ACTIVE MOLECULAR COMPLEX, METHOD FOR PRODUCING SINGLE-POLYMER PARTICLES, METHOD FOR MEASURING TUMOR SIZE, METHOD FOR MEASURING FINE STRUCTURE WITHIN TUMOR, METHOD FOR IMAGING BIOLOGICAL TISSUE, DRUG DELIVERY SYSTEM, AND CONTRAST AGENT KIT
1y 10m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
88%
With Interview (+9.4%)
2y 8m (~1y 9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 680 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month